BMS1044FI

antibody from Invitrogen Antibodies

Targeting: IFNB1 IFB, IFF, IFNB

Western blot (Recommended by provider)

ELISA (Recommended by provider)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

BMS1044FI

Provider

Invitrogen Antibodies

Product name

IFN beta Monoclonal Antibody (A1 (IFNb)), FITC, eBioscience™

Antibody type

Monoclonal

Antigen

Other

Description

Description: The IFNb/A1 clone recognizes natural human IFN-beta and recombinants beta1a and beta1b. It is capable of neutralizing IFN-beta. Interferon beta is synthesized and secreted by fibroblasts and many other cell types in response to pathogens. IFN-beta binding to type I interferon receptors induces the upregulation of IRF-7 and activation of Rnase L. IRF-7 can exert a positive feedback on IFN-beta production. RNase L cleaves both viral and cellular single stranded mRNA, thereby limiting viral replication and dissemination. Applications Tested: ELISA, Neutralization tests, Western Blotting. Excitation: 488 nm; Emission: 520 nm; Laser: Blue Laser

Reactivity

Human

Host

Mouse

Conjugate

Green dye

Isotype

IgG

Antibody clone number

A1 (IFNb)

Vial size

100 µg

Concentration

0.1 mg/mL

Storage

4° C, store in dark

References

Submitted references

Deubiquitination of proteasome subunits by OTULIN regulates type I IFN production.

Tao P, Wang S, Ozen S, Lee PY, Zhang J, Wang J, Han H, Yang Z, Fang R, Tsai WL, Yang H, Sag E, Topaloglu R, Aksentijevich I, Yu X, Zhou Q
Science advances 2021 Nov 19;7(47):eabi6794

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 1. Patients with otulipenia display overactivation of IFN-I signaling. ( A ) NanoString analysis of IFN-I signaling in whole blood samples from two patients, four healthy controls, and a type I interferonopathy patient control (PC) with deoxyribonuclease 2 deficiency. ( B ) Cytokine levels in whole blood samples. The whole blood samples from P1 and his unaffected sibling were stimulated with poly(I:C) (20 mug/ml) or LPS (1 mug/ml) for 22 hours. ( C ) Cytokine levels in the supernatant of cultured PBMCs from three patients and one healthy control. ( D ) Cytokine levels in the supernatant of purified monocytes from P1 and three healthy controls. Cells used to detect IP10 and monokine induced by IFN-gamma (MIG) were at basal level. Cells used to detect monocyte chemoattractant protein 1 (MCP1) were stimulated with LPS (1 mug/ml) for 48 hours. P1 was sampled twice. ( E ) Serum cytokine levels from three patients and seven healthy controls. ( F ) Intracellular cytokine staining of IFN-beta and RANTES (CCL5) in T cells and B cells of P3 and two healthy controls. ( G ) Phosphorylation of STAT1 and p65 of patient P3 T cells compared to two healthy controls at basal level and after IL-6 (100 ng/ml) stimulation for 6 hours as determined by flow cytometry analysis. The patients carry homozygous disease-associated variants in OTULIN: P1 (Leu 272 Pro), P2 (Tyr 244 Cys), and P3 (Gly 174 Aspfs*2).

Conjugate

Green dye